Darmstadt, Germany, February 15, 2021 — Merck, a leading science and technology company, has launched an enhanced Design for Sustainability (DfS) framework, a unique approach to holistically integrate sustainability into Life Science products, systems and services. With the introduction of DfS, Merck leads the life science industry in ensuring that sustainability is at the forefront of each stage of the product life cycle. This important strategic initiative supports the company’s commitment to integrate sustainability into all value chains by 2030, as outlined in its sustainability strategy.
“This approach has had a positive impact on Merck’s business internally, and now it also will benefit our customers across academia, pharma and industry — helping them make more informed decisions and surpass their own sustainability goals,” said Chris Ross, interim business sector head, Life Science, at Merck. “Using the DfS framework, Merck will offer a deeper level of data-driven insight to help guide customer conversations around greener, more sustainable alternatives.”
The DfS framework comprises three parts — Development, Consulting and Re-engineering — in which Merck identifies the sources of environmental impacts, defines relevant targets and measures product sustainability characteristics.
The DfS program is a cornerstone of Merck’s commitment to delivering sustainable business practices throughout the lifecycle of its Life Science products. This unparalleled approach allows the company to offer new products with smaller environmental footprints, while helping customers exceed their own sustainability targets in key areas such as energy, waste and water.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Performance Materials.
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.